Funding for this research was provided by:
Division of Clinical Research Promotion at the National Hospital Organization Shikoku Cancer Center
Text and Data Mining valid from 2019-08-12
Received: 26 April 2019
Accepted: 2 August 2019
First Online: 12 August 2019
Compliance with ethical standards
: AH received personal fees as honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, and Novartis Pharma. YS received personal fees as honoraria from AstraZeneca, Chugai Pharmaceutical, Pfizer, Eisai, Novartis Pharma, Taiho Pharmaceutical, and Takeda Pharmaceutical. MK received personal fees as honoraria from Chugai Pharmaceutical, Eisai, AstraZeneca, Pfizer, Taiho Pharmaceutical, Novartis Pharma, Takeda Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Shionogi, and Asashi Kasei. KA received personal fees as honoraria from Chugai Pharmaceutical, Eisai, AstraZeneca, Taiho Pharmaceutical, Novartis Pharma, Daiichi Sankyo, Mochida Pharmaceutical, Ono Pharmaceutical, and Eli Lilly Japan, and his institution received research funds from Chugai Pharmaceutical, Eisai and Sanofi. The other authors have no competing interests to declare.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee (No. 14-06 & 17-33) and with the 1964 Helsinki declaration and its later amendments.
: Formal consent was not required for this type of study.